Identifying Genetically-supported Drug Repurposing Targets for Non-small Cell Lung Cancer Through Mendelian Randomization of the Druggable Genome

Overview

Journal Transl Lung Cancer Res

Date 2024 Sep 12

PMID 39263038

Authors

Yi Feng

Caichen Li

Bo Cheng

Ying Chen

Peiling Chen

Zixun Wang

Xiangyuan Zheng

Juan He

Feng Zhu

Wei Wang

Wenhua Liang

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer is responsible for most cancer-related deaths, and non-small cell lung cancer (NSCLC) accounts for the majority of cases. Targeted therapy has made promising advancements in systemic treatment for NSCLC over the last two decades, but inadequate drug targets with clinically proven survival benefits limit its universal application in clinical practice compared to chemotherapy and immunotherapy. There is an urgent need to explore new drug targets to expand the beneficiary group. This study aims to identify druggable genes and to predict the efficacy and prognostic value of the corresponding targeted drugs in NSCLC.

Methods: Two-sample mendelian randomization (MR) of druggable genes was performed to predict the efficacy of their corresponding targeted therapy for NSCLC. Subsequent sensitivity analyses were performed to assess potential confounders. Accessible RNA sequencing data were incorporated for subsequent verifications, and Kaplan-Meier survival curves of different gene expressions were used to explore the prognostic value of candidate druggable genes.

Results: MR screening encompassing 4,863 expression quantitative trait loci (eQTL) and 1,072 protein quantitative trait loci (pQTL, with 453 proteins overlapping) were performed. Seven candidate druggable genes were identified, including , , and for lung adenocarcinoma, and , and for lung squamous cell carcinoma. The results were validated by further transcriptomic investigations.

Conclusions: Drugs targeting genetically supported genomes are considerably more likely to yield promising efficacy and succeed in clinical trials. We provide compelling genetic evidence to prioritize drug development for NSCLC.

References

King E, Davis J, Degner J . Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019; 15(12):e1008489. PMC: 6907751. DOI: 10.1371/journal.pgen.1008489. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Kamat M, Blackshaw J, Young R, Surendran P, Burgess S, Danesh J . PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. 2019; 35(22):4851-4853. PMC: 6853652. DOI: 10.1093/bioinformatics/btz469. View

Gill D, Cameron A, Burgess S, Li X, Doherty D, Karhunen V . Urate, Blood Pressure, and Cardiovascular Disease: Evidence From Mendelian Randomization and Meta-Analysis of Clinical Trials. Hypertension. 2020; 77(2):383-392. PMC: 7803439. DOI: 10.1161/HYPERTENSIONAHA.120.16547. View

Ali S, Dunmore H, Karres D, Hay J, Salmonsson T, Gisselbrecht C . The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia. Oncologist. 2019; 24(5):e171-e179. PMC: 6516123. DOI: 10.1634/theoncologist.2019-0025. View

Burgess S, Davey Smith G, Davies N, Dudbridge F, Gill D, Glymour M . Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2023; 4:186. PMC: 7384151. DOI: 10.12688/wellcomeopenres.15555.3. View

Bourgault J, Abner E, Manikpurage H, Pujol-Gualdo N, Laisk T, Gobeil E . Proteome-Wide Mendelian Randomization Identifies Causal Links Between Blood Proteins and Acute Pancreatitis. Gastroenterology. 2023; 164(6):953-965.e3. DOI: 10.1053/j.gastro.2023.01.028. View

Minikel E, Painter J, Dong C, Nelson M . Refining the impact of genetic evidence on clinical success. Nature. 2024; 629(8012):624-629. PMC: 11096124. DOI: 10.1038/s41586-024-07316-0. View

Wang G, Sarkar A, Carbonetto P, Stephens M . A simple new approach to variable selection in regression, with application to genetic fine mapping. J R Stat Soc Series B Stat Methodol. 2023; 82(5):1273-1300. PMC: 10201948. DOI: 10.1111/rssb.12388. View

10.

Mountjoy E, Schmidt E, Carmona M, Schwartzentruber J, Peat G, Miranda A . An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. Nat Genet. 2021; 53(11):1527-1533. PMC: 7611956. DOI: 10.1038/s41588-021-00945-5. View

11.

Wishart D, Feunang Y, Guo A, Lo E, Marcu A, Grant J . DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017; 46(D1):D1074-D1082. PMC: 5753335. DOI: 10.1093/nar/gkx1037. View

12.

Zuber V, Grinberg N, Gill D, Manipur I, Slob E, Patel A . Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. Am J Hum Genet. 2022; 109(5):767-782. PMC: 7612737. DOI: 10.1016/j.ajhg.2022.04.001. View

13.

Kim M, Yu K, Kenderian S, Ruella M, Chen S, Shin T . Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018; 173(6):1439-1453.e19. PMC: 6003425. DOI: 10.1016/j.cell.2018.05.013. View

14.

Revel M, Sautes-Fridman C, Fridman W, Roumenina L . C1q+ macrophages: passengers or drivers of cancer progression. Trends Cancer. 2022; 8(7):517-526. DOI: 10.1016/j.trecan.2022.02.006. View

15.

Planchard D, Janne P, Cheng Y, Yang J, Yanagitani N, Kim S . Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC. N Engl J Med. 2023; 389(21):1935-1948. DOI: 10.1056/NEJMoa2306434. View

16.

Riedel R, Fassunke J, Scheel A, Scheffler M, Heydt C, Nogova L . MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition. J Thorac Oncol. 2023; 19(1):160-165. DOI: 10.1016/j.jtho.2023.06.020. View

17.

Abecasis G, Auton A, Brooks L, DePristo M, Durbin R, Handsaker R . An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56-65. PMC: 3498066. DOI: 10.1038/nature11632. View

18.

Jacobs B, Taylor T, Awad A, Baker D, Giovanonni G, Noyce A . Summary-data-based Mendelian randomization prioritizes potential druggable targets for multiple sclerosis. Brain Commun. 2020; 2(2):fcaa119. PMC: 7519728. DOI: 10.1093/braincomms/fcaa119. View

19.

Cleary E, Jackson M, Zhou E, Ledley F . Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019. JAMA Health Forum. 2023; 4(4):e230511. PMC: 10148199. DOI: 10.1001/jamahealthforum.2023.0511. View

20.

Joehanes R, Zhang X, Huan T, Yao C, Ying S, Nguyen Q . Integrated genome-wide analysis of expression quantitative trait loci aids interpretation of genomic association studies. Genome Biol. 2017; 18(1):16. PMC: 5264466. DOI: 10.1186/s13059-016-1142-6. View